News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Acambis PLC Announces Results From Phase 1 Trial Of C. difficile Vaccine
February 15, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cambridge, UK and Cambridge, Massachusetts -15 February 2006 - Acambis plc (Acambis) (LSE: ACM, NASDAQ: ACAM) announces results from a Phase 1 trial of its investigational vaccine against Clostridium difficile (C. difficile) in healthy adults.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH API
Webinar: Lean Derisking: Taking Your Proof of Concept to the Clinic
February 24, 2026
·
1 min read
·
BioSpace Insights
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
·
1 min read
·
Nick Paul Taylor
Drug pricing
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss
February 24, 2026
·
3 min read
·
Jef Akst
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
February 24, 2026
·
2 min read
·
Tristan Manalac
